Xalatan and Avandia link to macular oedema in Australia
This article was originally published in Scrip
Executive Summary
Australia's adverse drug reactions advisory committee (ADRAC) says that it has received 25 ADR reports of drug-associated macular oedema to date, with seven related to Pfizer's glaucoma therapy latanoprost (Xalatan), and nine associated with GlaxoSmithKline 's'sdiabetes treatment Avandia (rosiglitazone). Other ADR reports came from NSAID (three reports) or bisphosphonate (three) use.